In the battle against cancer, you want every available weapon on your side. To help provide you with the most advanced cancer care, Lehigh Valley Topper Cancer Institute is a member of the Memorial Sloan Kettering (MSK) Cancer Alliance so we take your cancer fight to a new level. LVHN patients have access to MSK clinical trials, which accelerates the data-collection process so investigational treatments can be approved faster and become available to more patients. LVHN is currently participating in elite cancer trials, including the two below:
Targeted Agent and Profiling Utilization Registry (TAPUR)
Affiliated with the federal government’s Cancer Moonshot program to accelerate cancer research, the TAPUR study provides eligible patients with medication not yet approved by the FDA for their particular cancer type and collects data on the clinical response. LVHN is one of only two TAPUR sites in Pennsylvania.
LVHN patients ages 18 and older with recurrent glioblastoma may be eligible for the CAPTIVE study. Lehigh Valley Hospital–Cedar Crest is the only hospital in the region participating in the trial, which is sponsored by biotechnology company DNAtrix in conjunction with Merck.
Find out more information by clicking the links below.